FDA expedites review of BioMarin's rare-disease drug Vimizim

05/31/2013 | RTT News

The FDA has accepted BioMarin Pharmaceutical's biologics license application for Vimizim, or BMN-110, elosulfase alfa, an experimental treatment for Mucopolysaccharidosis type IVA, also known as Morquio A Syndrome. The enzyme replacement therapy was granted a priority-review status.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY